Immune checkpoint inhibitors (ICIs), frequently designated as third-generation cancer treatments, have been shown to reinvigorate the anti-tumor activity of suppressed T cells by obstructing immune checkpoint pathways such as PD-1/PD-L1. This evidence concerns the gene CD274 and neoplasm.